TY - JOUR T1 - The Canadian Rheumatology Association/ Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. JF - The Journal of Rheumatology JO - J Rheumatol SP - 2273 LP - 2284 VL - 34 IS - 11 AU - Walter P Maksymowych AU - Dafna Gladman AU - Proton Rahman AU - Annelies Boonen AU - Vivien Bykerk AU - Denis Choquette AU - Sherry Dimond AU - Paul Fortin AU - Jacob Karsh AU - Alice V Klinkhoff AU - Dianne Mosher AU - Ken Mulholland AU - Wojciech P Olszynski AU - Anthony S Russell AU - Laurie Savage AU - Laura Shanner AU - Kam Shojania AU - Michael Starr AU - Glen Thomson AU - Michel Zummer AU - Robert Inman AU - Canadian Rheumatology Association/ Spondyloarthritis Research Consortium of Canada Y1 - 2007/11/01 UR - http://www.jrheum.org/content/34/11/2273.abstract N2 - OBJECTIVE: Development of treatment recommendations for arthritis has traditionally relied on the compilation of evidence-based data by experts in the field despite recommendations by various bodies for broad stakeholder input. Our objectives were: (1) To develop evidence-based treatment recommendations for the management of spondyloarthritis (SpA) in Canada that also incorporate the perspective of multiple stakeholders. (2) To generate a procedural template for the multidisciplinary development of treatment recommendations. METHODS: The process was directed by a steering committee comprising the SPARCC Executive, rheumatologists from academic and community-based practice, patient consumers, and a representative from the John Dossetor Health Ethics Centre. Guidelines established by EULAR and stipulated in the AGREE instrument were followed. First, a working document was drafted that included a referenced summary of the evidence-based data and the 12 national arthritis care standards developed by the Alliance for the Canadian Arthritis Program. Second, a Web-based survey was conducted among patient consumers to address the relevance to patients of 2 primary outcome instruments that assess the effectiveness of treatment. Third, a list of questions was generated for drafting propositions by the ethics consultant. A Delphi consensus exercise was then conducted. RESULTS: Consensus was generated on a final list of 38 treatment recommendations categorized under the subject headings of general management principles, ethical considerations, target groups, definition of target disease, disease monitoring, and specific management recommendations. CONCLUSION: Using broad stakeholder input, we provide treatment recommendations to guide clinical practice and access to care for patients with SpA in Canada. ER -